Abstract 534P
Background
Lung cancer is a major health concern worldwide. It is the leading cause of cancer-related deaths among both men and women. The current study aims to investigate the role of desmocollin 2 (DSC2) protein in the proliferation, migration, drug resistance and immunotherapy of lung cancer cells. Lung cancer is a major health concern worldwide.
Methods
To examine the role of DSC2 in lung cancer cells, various assays were performed, including CCK-8 and colony formation assays to assess the impact on cell viability and colony formation, respectively. Transwell and wound-healing assays were also conducted to evaluate the impact on cell migration. The flow cytometry double staining assay was employed to detect the apoptosis rate of cells with DSC2 added with cisplatin. Western blotting analysis was used to examine the levels of cell cycle, PI3k/Akt, and apoptosis-related proteins.
Results
The results of this study revealed that DSC2 is upregulated in clinical lung cancer tissues compared to pericarcinomatous tissues and differentially expressed in lung cancer cell lines. The down-regulation of DSC2 in A549 and H358 lung cancer cells significantly reduced cell proliferation, metastasis, and motility. In addition to lung adenocarcinoma cell lines, we also examined its expression in lung squamous cell lines, such as H226. However, the overexpression of DSC2 in H23 and PC9 cell lines showed opposite effects. Western blotting showed that DSC2 could reduce the level of phosphorylated Akt (Ser 473) and p-mTOR. Thus, the study suggested that DSC2 up-regulation promotes proliferation and invasiveness through activation of the PI3K/AKT pathway. DSC2 knockdown can significantly decrease the levels of cyclinB and wee1 protein in A549 and H226. Cisplatin combined with DSC2 knockdown can enhance cell apoptosis rates.
Conclusions
These data suggest that dsc2 promotes the proliferation and migration of lung cancer cells in vitro. Also, the results suggested that dsc2 could affect the cell cycle and apoptosis of lung cells. Furthermore, knockdown of dsc2 could sensitize cisplatin in both lung adenocarcinoma and lung squamous cell lines. Thus, we suggested that dsc2 can be used as a therapeutic target for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Affiliated Hangzhou First People’s Hospital of Zhejiang university.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract